MCID: MLG002
MIFTS: 42

Malignant Peritoneal Mesothelioma

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

MalaCards integrated aliases for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 58 17
Diffuse Malignant Peritoneal Mesothelioma 58
Primary Malignant Peritoneal Mesothelioma 58
Malignant Mesothelioma of Peritoneum 70

Characteristics:

Orphanet epidemiological data:

58
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

ICD10 via Orphanet 33 C45.1
UMLS via Orphanet 71 C0346109
Orphanet 58 ORPHA168811
UMLS 70 C0346109

Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to benign mesothelioma and peritoneal mesothelioma, and has symptoms including abdominal pain An important gene associated with Malignant Peritoneal Mesothelioma is BIRC5 (Baculoviral IAP Repeat Containing 5), and among its related pathways/superpathways are Cytoskeletal Signaling and Platinum drug resistance. The drugs Cisplatin and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and lung, and related phenotypes are ascites and abdominal pain

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 benign mesothelioma 31.9 NF2 CDKN2A
2 peritoneal mesothelioma 31.0 NF2 MUC1 EGFR CDKN2A BAP1
3 mesothelioma, malignant 30.4 NF2 MUC1 CDKN2A BAP1
4 verrucous carcinoma 30.1 EGFR CDKN2A
5 pleural disease 30.0 NF2 EGFR BAP1
6 ocular melanoma 29.8 CDKN2A BAP1
7 neurilemmoma 29.7 NF2 MUC1
8 well-differentiated liposarcoma 29.6 MUC1 CDKN2A
9 ewing sarcoma 29.6 EGFR CDKN2A BAP1
10 dedifferentiated liposarcoma 29.5 MUC1 CDKN2A
11 squamous cell carcinoma 29.4 MUC1 EGFR CDKN2A
12 sarcomatoid mesothelioma 29.4 MUC1 CDKN2A BAP1
13 adenocarcinoma 29.3 MUC1 EGFR CDKN2A BIRC5
14 lung cancer susceptibility 3 29.3 MUC1 EGFR CDKN2A BIRC5
15 peritoneum cancer 29.2 NF2 EGFR CDKN2A BAP1
16 melanoma, uveal 29.2 NF2 EGFR CDKN2A BAP1
17 melanoma 29.1 NF2 EGFR CDKN2A BIRC5 BAP1
18 esophageal cancer 29.0 MUC1 EGFR CDKN2A BIRC5
19 malignant pleural mesothelioma 29.0 NF2 MUC1 EGFR CDKN2A BIRC5 BAP1
20 rare tumor 10.6
21 asbestosis 10.4
22 thrombocytosis 10.4
23 asbestos intoxication 10.4
24 ovarian cancer 10.4
25 benign intermediate mesothelioma 10.3
26 peritonitis 10.3
27 intestinal obstruction 10.3
28 inguinal hernia 10.3
29 seminoma 10.3
30 familial mediterranean fever 10.2
31 gastrointestinal stromal tumor 10.2
32 brucellosis 10.2
33 pseudomyxoma peritonei 10.2
34 pulmonary fibrosis 10.2
35 tuberculous peritonitis 10.2
36 primary peritoneal carcinoma 10.2
37 adenosquamous lung carcinoma 10.2 EGFR BIRC5
38 renal cell carcinoma, nonpapillary 10.1
39 lung cancer 10.1
40 inflammatory bowel disease 10.1
41 hydrocephalus 10.1
42 disseminated intravascular coagulation 10.1
43 endometriosis 10.1
44 lung squamous cell carcinoma 10.1
45 gastritis 10.1
46 liver cirrhosis 10.1
47 appendicitis 10.1
48 hydrocele 10.1
49 testicular seminoma 10.1
50 thyroid carcinoma 10.1

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 58 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 neoplasm 58 31 hallmark (90%) Very frequent (99-80%) HP:0002664
4 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
5 peritonitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002586
6 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
7 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
8 abnormality of coagulation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001928
9 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
10 ileus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002595

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.62 NF2
2 Decreased cell migration GR00055-A-3 8.62 EGFR

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.55 BAP1 BIRC5 CDKN2A EGFR NF2
2 endocrine/exocrine gland MP:0005379 9.35 BAP1 BIRC5 CDKN2A EGFR NF2
3 neoplasm MP:0002006 8.92 BAP1 CDKN2A EGFR NF2

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 16)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
2
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
3
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
4
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
5
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
6
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
7
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
8 Protein Kinase Inhibitors Phase 2
9 Vitamin B9 Phase 2
10 Antibiotics, Antitubercular Phase 2
11 Folic Acid Antagonists Phase 2
12
Liposomal doxorubicin Phase 2 31703
13 Vitamin B Complex Phase 2
14 Folate Phase 2
15 Anti-Bacterial Agents Phase 2
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations Completed NCT01592383 Phase 2 erlotinib hydrochloride
2 Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma Recruiting NCT03875144 Phase 2 Cisplatin;Pemetrexed
3 A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients Not yet recruiting NCT04462809 Phase 2 Talazoparib

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

40
Lymph Node, Colon, Lung, Testis, Small Intestine, Uterus, Prostate

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 584)
# Title Authors PMID Year
1
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells. 61
33530027 2021
2
Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". 61
33318658 2021
3
Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". 61
33339893 2021
4
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. 61
33743636 2021
5
A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review. 61
33555117 2021
6
Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters. 61
32826527 2021
7
Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. 61
33633025 2021
8
Nivolumab activity in advanced refractory malignant peritoneal mesothelioma. 61
33358840 2021
9
Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases. 61
33577225 2021
10
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. 61
33100328 2021
11
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. 61
33060816 2021
12
The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. 61
32808135 2021
13
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma. 61
33473097 2021
14
Malignant peritoneal mesothelioma presenting as a splenic mass. 61
33161309 2020
15
Unusual radiologic presentations of malignant peritoneal mesothelioma. 61
33510855 2020
16
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. 61
33073341 2020
17
ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities. 61
32239340 2020
18
Parahiatal hernia sac tumor of localized malignant peritoneal mesothelioma. 61
33359504 2020
19
Massive Ascites Secondary to Malignant Peritoneal Mesothelioma. 61
31982608 2020
20
Forecast of Malignant Peritoneal Mesothelioma Mortality in Italy up to 2040. 61
33379304 2020
21
A case of sarcomatoid malignant peritoneal mesothelioma diagnosed by laparoscopy. 61
33015277 2020
22
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. 61
33185798 2020
23
Molecular characterization of diffuse malignant peritoneal mesothelioma. 61
32504035 2020
24
Nivolumab for malignant peritoneal mesothelioma. 61
33257382 2020
25
A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT. 61
32604114 2020
26
Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome. 61
32581164 2020
27
ALK positive malignant peritoneal mesothelioma mimicking inflammatory myofibroblastic tumour: a diagnostic pitfall. 61
32814620 2020
28
A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT. 61
32558713 2020
29
Sarcomatoid malignant peritoneal mesothelioma presenting as a localized mesenteric tumor with no previous asbestos exposure. 61
33149886 2020
30
ASO Author Reflections: Expert Surgical Evaluation is Critical for Patients with Diffuse Malignant Peritoneal Mesothelioma: Lessons Learned from Assessing Outcomes of 2000 Patients. 61
32274661 2020
31
Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database. 61
32006127 2020
32
Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study. 61
32764701 2020
33
Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series. 61
31832913 2020
34
Osteopontin, GLUT1 and Ki67 expression in malignant peritoneal mesothelioma: Prognostic implications. 61
32510678 2020
35
Localized biphasic malignant peritoneal mesothelioma presenting as a rectal tumor. 61
31602554 2020
36
Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma. 61
32382335 2020
37
Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. 61
32561104 2020
38
Multicystic and diffuse malignant peritoneal mesothelioma in children. 61
32277799 2020
39
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study. 61
32526924 2020
40
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. 61
32669924 2020
41
[Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma]. 61
32536066 2020
42
Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report. 61
32481365 2020
43
Localized biphasic malignant mesothelioma presenting as a giant pelvic wall mass: a rare case report and literature review. 61
32375654 2020
44
Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge. 61
32509926 2020
45
Endoscopic ultrasound-guided fine-needle biopsy for definitive diagnosis of malignant peritoneal mesothelioma. 61
31860155 2020
46
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. 61
31986452 2020
47
[Establishment and characterization of patient derived xenograft model of malignant peritoneal mesothelioma in nude mice]. 61
32074730 2020
48
Peritoneal mesothelioma. 61
32206577 2020
49
[Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis]. 61
32050285 2020
50
18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma. 61
31876833 2020

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

Pathways related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.62 NF2 MUC1 BAP1
2 11.18 CDKN2A BIRC5
3 11.12 EGFR CDKN2A
4 10.86 EGFR CDKN2A
5 10.84 NF2 EGFR CDKN2A

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.33 NF2 CDKN2A BAP1
2 negative regulation of cell-matrix adhesion GO:0001953 8.96 NF2 CDKN2A
3 regulation of cell cycle GO:0051726 8.8 NF2 BIRC5 BAP1

Molecular functions related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 p53 binding GO:0002039 8.62 MUC1 CDKN2A

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....